(Total Views: 151)
Posted On: 04/17/2017 6:41:34 PM
Post# of 2218
$NTCHF Nanoparticles enable physicians to target drugs at the source of the disease, which increases efficiency and minimizes side effects.
NTCHF or N1 Technologies Inc. is a Global leader in the Research & Development of nanotechnology innovations, in the fields of nanotechnology and Biotechnology. The company has evolved since 2013 into a pure Bio-Tech enterprise. Originally the company manufactured a small number of its patented nanotechnology based products and marketed them to a worldwide consumer base. Over the last year the company has focused on R&D for future licensing of it's patented Viritron VDX, VPN and Mini Lab anti-bacterial treatments for Staphylococcus and Streptococcus bacterial infections. The company intends to enter this $30 Billion dollar market as a major supplier of anti-bacterial Genetically Modified Organisms, that offer an effective treatment for life threatening infections.
Just this past fall NTCHF’s Q3’s were posted on PRNEWSWIRE:
The directors and management of N1 Technologies Inc. (OTC PINK: NTCHF) reported results for the fiscal 2016 third quarter ended September 30, 2016.
NTCHF’s net assets for the fiscal 2016 third quarter were USD15.5 MILLION! A dramatic increase over the previous quarter.
NTCHF is a Global leader in the Research & Development of nanotechnology innovations, in the fields of nanotechnology and Biotechnology. Originally the company manufactured a small number of its patented nanotechnology based products and marketed them to a worldwide consumer base.
More on that click here: http://www.prnewswire.com/news-releases/n1-te...57390.html
NTCHF or N1 Technologies Inc. is a Global leader in the Research & Development of nanotechnology innovations, in the fields of nanotechnology and Biotechnology. The company has evolved since 2013 into a pure Bio-Tech enterprise. Originally the company manufactured a small number of its patented nanotechnology based products and marketed them to a worldwide consumer base. Over the last year the company has focused on R&D for future licensing of it's patented Viritron VDX, VPN and Mini Lab anti-bacterial treatments for Staphylococcus and Streptococcus bacterial infections. The company intends to enter this $30 Billion dollar market as a major supplier of anti-bacterial Genetically Modified Organisms, that offer an effective treatment for life threatening infections.
Just this past fall NTCHF’s Q3’s were posted on PRNEWSWIRE:
The directors and management of N1 Technologies Inc. (OTC PINK: NTCHF) reported results for the fiscal 2016 third quarter ended September 30, 2016.
NTCHF’s net assets for the fiscal 2016 third quarter were USD15.5 MILLION! A dramatic increase over the previous quarter.
NTCHF is a Global leader in the Research & Development of nanotechnology innovations, in the fields of nanotechnology and Biotechnology. Originally the company manufactured a small number of its patented nanotechnology based products and marketed them to a worldwide consumer base.
More on that click here: http://www.prnewswire.com/news-releases/n1-te...57390.html
(0)
(0)
